Videos

At MAD-ID, Marc Scheetz, PharmD, discusses how PK/PD modeling and AUC-based strategies offer safer, more precise antibiotic therapy.

Logan Brock, PharmD, presents data at MAD-ID, showing limited diagnostic yield from routine fungal cultures and delayed results compared with standard methods.

After the leaders of the NIH, FDA, and HHS made an announcement stating that both pregnant women and children were going to be taken off the COVID-19 immunization schedule, they decided to offer a new designation for the latter group, making it a shared decision between providers and patients.

At MAD-ID 2025, Kimberly Leuthner, PharmD, FIDSA, highlights the need for larger prospective studies amid limited current evidence.

At MAD-ID 2025, Jiye Park, PharmD, presents findings showing once-daily dosing is effective, with no added benefit from extended vancomycin use after antibiotics.

At MAD-ID 2025, Dakota Rorie, PharmD, highlights cost and access barriers to uptake of preferred CDI therapy.

At MAD-ID 2025, Rachel M. Kenney, PharmD, discusses treatment shifts, microbiome innovations, and pharmacists' roles in optimizing outcomes.

Timmy Do, PharmD, BCIDP, BCPS, presents case series at MAD-ID 2025 on investigational therapies following tecovirimat failure.

At MAD-ID 2025, Cadhan McFadden presents data from a multidisciplinary ambulatory care project using PEN-FAST scoring and oral challenges to improve antibiotic access and accuracy.

At MAD-ID 2025, Elizabeth Dodds Ashley, PharmD, MHS, explains how NHSN’s Antibiotic Resistance Option is shaping stewardship and clinical decision-making.

At MAD-ID, a study highlights how prescribing in these settings suggests a need for antimicrobial stewardship efforts.

At MAD-ID, Timothy Aungst, PharmD, outlines the role of artificial intelligence in clinical decision-making, curriculum design, and infectious disease practice.

Part 2 of insights from Robert Bransfield, MD's research on the immune system’s role in psychiatric disorders.

Robert Bransfield, MD, introduces his understanding of how infectious diseases may trigger or worsen psychiatric disorders through genetics, immune response, and environmental factors.

A panel discusses how vaccine policy under new federal government policies, why misinformation has flourished and what individual providers can do to win back patient trust.

Paul Feuerstadt, MD, discuses the treatment’s overall safety and efficacy profile and provides insights on data around smaller subsets of patients with comorbidities.

Alexander Laurenson presents T-cell-focused tool at the 2025 Vaccinology Conference using data from 18 countries and 748 HLA alleles to address immune diversity in Africa.

New meta-analysis at the 2025 vaccinology conference highlights the efficacy of maternal RSV vaccines, with calls for enhanced monitoring following safety issues with one candidate

More than 80% of adults support COVID-19 vaccination, but hesitancy linked to side effects, geopolitics, and misinformation remains a challenge, says lead researcher Mahmud Sheku, MPH, MSc.

Zandraetta Tims-Cook, MD, MPH, highlights the need for inclusive HIV prevention strategies and discusses the potential of long-acting injectable PrEP in improving care and reducing disparities.

Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases discusses the results of the organization's new survey and the surprising findings that many people forget to wash their hands after key times or believe it is not needed.

As therapies that impact the immune system become more common, patients are living longer but with increased susceptibility to infections, including viral, bacterial, fungal, and emerging diseases.

Therapeutic vaccines GS-2829 and GS-6779 demonstrate immune responses and strong safety profile, showing potential to contribute to global hepatitis B elimination efforts.

Pertussis, also known as whooping cough, saw more cases last year than in the last decade, and it is on track for another record year for cases. Sharon Nachman, MD, provides clinical insights for presentation, treatment, and vaccination.

Multinational real-world analysis underscores the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) across diverse populations and highlights the need for timely treatment initiation to improve patient outcomes.

Paul Feuerstadt, MD, discusses the safe and effective use of RBL in preventing C difficile recurrence with positive physician feedback and high patient benefit

Anu Osinusi, MD, discusses the findings examining bulevirtide as a standalone therapy and in combination with pegylated interferon alpha.

Paul Offit, MD, offers insights on the state of measles today where some families are opting to believe treatment is a better option than vaccination. He also discusses the potential toxicity of vitamin A treatment, as well as the limitations of supportive treatment for the disease.

Jason Barker, ND, explains how in-house technology delivers highly sensitive specific and early detection of Borrelia infections and co-infections helping patients receive faster diagnosis and treatment

Jason Barker, ND, details how Vibrant’s platform raises diagnostic sensitivity from 63% to 100%, ensuring more accurate detection and faster treatment for Lyme disease and tick-borne infections.